Quetiapine XR in the Treatment of Comorbid Generalized Anxiety Disorder in Bipolar Depression With or Without Substance Use Disorder

Trial Profile

Quetiapine XR in the Treatment of Comorbid Generalized Anxiety Disorder in Bipolar Depression With or Without Substance Use Disorder

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Bipolar depression; Bipolar I disorders; Bipolar II disorders; Generalised anxiety disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 May 2013 Primary endpoint 'Hamilton-Depression-Rating-Scale' has not been met.
    • 18 May 2013 Results presented at the 166th Annual Meeting of the American Psychiatric Association.
    • 31 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top